Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 2/20 | 0.47 |
| ▸ | RET | P07949 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.43 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 2/20 | 0.41 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 3/20 | 0.40 |
| ▸ | DRD3 | P35462 | 3/20 | 0.40 |
| ▸ | DRD2 | P14416 | 2/20 | 0.40 |
| ▸ | HTR1A | P08908 | 2/20 | 0.40 |
| ▸ | HTR2A | P28223 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20804885 | 0.83 | MAPT (0.61) | CHRM4ALDH1A1MAPTNPBWR1MCHR1 | |
| SCHEMBL27798357 | 0.76 | SIGMAR1 (0.62) | ALDH1A1CYP2D6MEN1KMT2ATSHR | |
| SCHEMBL25696351 | 0.76 | AVPR1A (0.45) | DRD4DRD3DRD2HTR1AHTR2A | |
| SCHEMBL25720129 | 0.75 | GRM1 (0.40) | ALDH1A1AVPR2 | |
| SCHEMBL14892774 | 0.74 | DRD4 (0.59) | CYP2D6MEN1KMT2ATSHRDRD4 | |
| SCHEMBL20798102 | 0.73 | AVPR1A (0.44) | ALDH1A1PARP1PARP2CYP1A2AVPR2 | |
| SCHEMBL14089988 | 0.72 | MC4R (0.58) | ALDH1A1CYP2D6MEN1KMT2ATSHR | |
| SCHEMBL17706684 | 0.72 | SIGMAR1 (0.52) | ALDH1A1CYP2D6MEN1KMT2ATSHR | |
| SCHEMBL30058086 | 0.71 | GRM1 (0.48) | ALDH1A1CYP2D6TSHRCYP2C9AVPR2 | |
| SCHEMBL22756724 | 0.71 | DHFR (0.42) | AVPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12152038-B2 | Vasopressin receptor antagonists and products and methods related thereto | Neumora Therapeutics, Inc. (US) | 2024-11-26 | — | — | US | disclosed |
| EP-3679043-B9 | VASOPRESSIN RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO | NEUMORA THERAPEUTICS INC (US) | 2023-09-27 | — | — | EP | disclosed |
| EP-3679043-B9 | VASOPRESSIN RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO | NEUMORA THERAPEUTICS INC (US) | 2023-09-27 | — | — | EP | disclosed |
| EP-3679043-B1 | VASOPRESSIN RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO | NEUMORA THERAPEUTICS INC (US) | 2023-05-31 | — | — | EP | disclosed |
| EP-3679043-B1 | VASOPRESSIN RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO | NEUMORA THERAPEUTICS INC (US) | 2023-05-31 | — | — | EP | disclosed |
| US-20210317126-A1 | VASOPRESSIN RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO | BLACKTHORN THERAPEUTICS, INC. | 2021-10-14 | — | — | US | disclosed |
| US-20210317126-A1 | VASOPRESSIN RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO | BLACKTHORN THERAPEUTICS, INC. | 2021-10-14 | — | — | US | disclosed |
| EP-3679043-A1 | VASOPRESSIN RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO | Blackthorn Therapeutics, Inc. (US) | 2020-07-15 | — | — | EP | disclosed |
| US-20190169202-A1 | VASOPRESSIN RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO | Neumora Therapeutics, Inc. | 2019-06-06 | — | — | US | disclosed |
| US-20190169202-A1 | VASOPRESSIN RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO | Neumora Therapeutics, Inc. | 2019-06-06 | — | — | US | disclosed |
| WO-2019050988-A1 | VASOPRESSIN RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO | BLACKTHORN THERAPEUTICS, INC. (US) | 2019-03-14 | — | — | WO | disclosed |
| WO-2019050988-A1 | VASOPRESSIN RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO | BLACKTHORN THERAPEUTICS, INC. (US) | 2019-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12152038-B2 | Vasopressin receptor antagonists and products and methods related thereto | AVPR1A, AVPR2, AVPR1B | CHRM4 732/4885RET 936/4885ALDH1A1 2907/4885 |
| US-20210317126-A1 | VASOPRESSIN RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO | AVPR1A, AVPR2, AVPR1B | CHRM4 732/4885RET 936/4885ALDH1A1 2907/4885 |
| US-20190169202-A1 | VASOPRESSIN RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO | AVPR1A, AVPR2, AVPR1B | CHRM4 732/4885RET 936/4885ALDH1A1 2907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.